Cardio Diagnostics Holdings, Inc. (CDIOW) stock
Close on Oct 30, 2026Market cap $4.94MP/E –Yield –
Cardio Diagnostics Holdings, Inc. saw revenue fall 57.5% to $14.83K over the twelve months to Dec 31, 2025. Free cash flow was -$5.91M. At the latest close the market valued the company at $4.94M.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $4.94M
- P/E ratio
- –
- Price to sales
- 333.38
- Price to book
- 0.67
- Dividend yield
- –
- Free cash flow yield
- -119.66%
Fundamentals
- Revenue
- $14.83K
- Net income
- -$6.50M
- EPS, diluted
- -$3.71
- Free cash flow
- -$5.91M
- Book value per share
- $2.51
- Diluted shares
- 3M
Trading
- Previous close
- $0.01
- Open
- $0.01
- Day's range
- $0.01 – $0.01
- Volume
- 28,821
- Average volume (20 days)
- 22,647
- Beta (5 years)
- 2.64
- 52-week range
- $0.97 – $7.91
- RSI (14 days)
- 41.0
- Volatility (1 year)
- 148.0%
- Relative volume
- 0.25×
- WACC
- 17.5%
Market cap history
Month-end market cap since 2022, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Oct 30, 2026. The S&P 500 is measured by the SPY fund.
| Period | CDIOW | S&P 500 | Difference | CDIOW per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | +14.0% | -0.9% | +14.9 pts | ||
| 3 months | -30.0% | +2.1% | −32.1 pts | ||
| Year to date | -62.2% | +11.7% | −73.9 pts | ||
| 1 year | -54.8% | +12.4% | −67.2 pts | ||
| 3 years | -75.5% | +88.6% | −164.1 pts | -37.4% | +23.5% |
Six years at a glance
Fiscal years 2020 to 2025, USD
Revenue
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Cardio Diagnostics filed with the SEC as exhibits to Form 8-K or 6-K
- Update
- Update
- Update
- Update
- Update
- News
About Cardio Diagnostics
In Vitro & In Vivo Diagnostic Substances
Cardio Diagnostics Holdings, Inc. develops and commercializes artificial intelligence-driven, epigenetics-based clinical blood tests and platforms for cardiovascular disease. The company's core product offerings include Epi+Gen CHD, a test designed to assess the three-year risk of symptomatic coronary heart disease events, and PrecisionCHD, a test used to detect coronary heart disease alongside actionable clinical intelligence. In addition, the firm offers HeartRisk, a cardiovascular risk intelligence platform, and CardioInnovate360, a research-use-only tool supporting biopharmaceutical discovery and development. Its diagnostic solutions serve patients, healthcare providers, health systems, self-insured employers, and payors.
Company profile, executives and historyCardio Diagnostics stock: common questions
What is Cardio Diagnostics's stock price?
CDIOW closed at $0.01 on Oct 30, 2026, up 0.00% on the day. Over the past 52 weeks it traded between $0.97 and $7.91.
What is Cardio Diagnostics's market cap?
Cardio Diagnostics was worth $4.94M at the close on Oct 30, 2026: the share price times the diluted shares outstanding.
What is CDIOW's P/E ratio?
Cardio Diagnostics lost money over the twelve months to Dec 31, 2025 (diluted EPS -$3.71), so it has no meaningful P/E ratio.
How much revenue does Cardio Diagnostics make?
Cardio Diagnostics reported revenue of $14.83K for the twelve months to Dec 31, 2025, down 57.5% from a year earlier.
Does Cardio Diagnostics pay a dividend?
No. Cardio Diagnostics has not paid a cash dividend over the last twelve months.
How has CDIOW stock performed over the past year?
Including dividends, CDIOW returned -54.8% over the past year, against +12.4% for the S&P 500.
Who are Cardio Diagnostics's competitors?
Companies most similar to Cardio Diagnostics by business, industry and size include VRAX, ADTX, AWHL, PRFX, BDPT.